Pluri Stock Price, News & Analysis

Pluri Inc. (NASDAQ, TASE: PLUR) is a biotechnology company focused on cell-based products and technologies. The company describes itself as pioneering mass-scale cell expansion and biofarming, using a patented, proprietary 3D cell expansion platform to develop scalable, consistent and cost-efficient cell-based solutions. According to its public communications, Pluri applies this platform across regenerative medicine, foodtech, agtech, aesthetics and Contract Development and Manufacturing Organization (CDMO) services, with the goal of addressing global challenges such as sustainable food production, healthcare and climate resilience.

Pluri states that its 3D cell expansion system is a validated, state-of-the-art technology designed to grow cells from diverse sources in a controlled, automated environment. The platform is described as accurate, scalable, cost-effective and consistent from batch to batch. This technology underpins Pluri’s efforts to create cell-based pharmaceuticals, food products and agricultural goods, and to support external partners through CDMO activities. The company highlights two decades of experience and a strong intellectual property portfolio, including patents related to immune cell expansion and activation in large scale within its proprietary bioreactors.

Core technology and cell expansion platform

Pluri’s technology platform centers on a 3D cell expansion system that the company uses to produce cells at commercial scale. Public descriptions emphasize that the bioreactor system mimics a natural, tissue-like or lymph node-like environment, providing tightly controlled conditions for cell growth. This approach is intended to enable efficient expansion of various cell types while maintaining their integrity, functionality and therapeutic potential. Pluri reports that this platform supports applications ranging from immune cell therapies to cell-based food and agriculture products.

The company has disclosed that its intellectual property estate includes a large number of patents pending, allowed and granted, and that recent patents cover systems and methods for immune cell expansion and activation in large scale. These patents include technologies for expanding Mucosal-Associated Invariant T (MAIT) cells and other immune cells in its 3D bioreactors, which Pluri views as important for potential future immunotherapy applications.

Biopharmaceutical and regenerative medicine activities

In the healthcare field, Pluri describes itself as operating in regenerative medicine and immunotherapy. Earlier disclosures referenced placenta-based cell therapy product candidates such as PLX-PAD and PLX-R18 for inflammatory, muscle and hematologic conditions. More recent communications emphasize an immune cell platform, including placental-derived MAIT cells and Tumor Infiltrating Lymphocytes (TILs) expanded using the company’s 3D technology. Pluri states that its placental MAIT cells are unconventional immune T cells that may be suitable for solid tumor treatment, and that its technology has addressed historical challenges in expanding these cells outside the human body.

The company has also reported collaborations in medical and emergency preparedness contexts. For example, it has discussed work on PLX-R18 for Acute Radiation Syndrome with support from U.S. government agencies, and a collaboration with Hemafund Ltd. to develop nuclear emergency response plans in Europe. These activities reflect Pluri’s stated aim to apply its cell expansion expertise to medical and public health challenges.

Foodtech and agtech ventures

Pluri positions foodtech and agtech as major areas of focus, using its cell expansion platform to develop cultivated, cell-based alternatives to traditional agricultural products. The company has described its strategy as building a collaborative network of ventures that apply its technology to specific markets.

Pluri has disclosed several subsidiaries and collaborations in this area:

• Ever After Foods Ltd. – A company in which Pluri reports holding a majority stake, leveraging Pluri’s cell expansion technology for cultivated meat production. Ever After Foods is described as operating a business-to-business model, working with food companies and cultivated-meat players on scale-up validation and pre-commercial trials.
• Kokomodo Ltd. – An AgFoodTech company specializing in cultivated cacao production. Pluri completed the acquisition of approximately 71% of Kokomodo, combining its mass-scale cell production expertise with Kokomodo’s cellular agriculture technology for real, controlled, climate-resilient cacao. Kokomodo cultivates cacao directly from plant cells to preserve flavor, functionality and nutritional qualities while reducing environmental and supply chain challenges.
• Coffeesai Ltd. – A wholly owned subsidiary developing sustainable, cell-based coffee products. Coffeesai creates coffee in controlled environments rather than traditional fields, aiming to reduce deforestation, water usage and pesticide dependence. The company has announced collaborations, including an agreement with the Instituto del Café de Chiapas in Mexico to advance cell-based coffee manufacturing through a phased roadmap from cell line development to potential commercial-scale production.

Through these ventures, Pluri presents its platform as a way to address issues such as climate change impacts on crops, resource constraints and supply chain instability, while working with global partners in Asia, Europe, the United States and Latin America.

Aesthetics and beauty collaborations

Pluri has expanded into health and aesthetics through the launch of Cellav Health and Aesthetics Ltd., a wholly owned subsidiary focused on regenerative, science-driven solutions for beauty and wellness. Cellav uses Pluri’s 3D cell expansion platform to develop exosome-based and other cell-derived ingredients for skincare and haircare. The subsidiary plans to offer premium cell-derived ingredients, professional-use and consumer-ready products, and a flexible technology platform for partners.

Cellav’s first disclosed commercial collaboration is with Miss Universe Skincare, a global skincare and beauty brand. Under this collaboration, Cellav is expected to supply a proprietary cell-based active ingredient for a new line of skincare products under the Miss Universe Skincare label, providing Pluri with exposure to the global beauty market through a business-to-business model.

CDMO services and partnerships

Pluri operates a CDMO division, PluriCDMO, which it launched to offer contract development and manufacturing services to external clients. The company indicates that PluriCDMO leverages its proprietary knowledge, technology and cell therapy production facility, including state-of-the-art Good Manufacturing Practice (GMP) infrastructure and its patented bioreactor system. Clients gain access to this facility and technology for mass-scale cell expansion via a controlled, automated and validated process.

Public announcements highlight collaborations such as the expanded agreement with Remedy Cell Ltd., a biopharmaceutical company developing stem cell-derived, cell-free therapeutics for fibrotic conditions. Under this collaboration, PluriCDMO has implemented Remedy Cell’s proprietary manufacturing process at Pluri’s GMP facility, conducted GMP training and qualification, executed engineering runs and manufactured clinical-grade batches for Remedy Cell’s initial Phase 1b clinical trial. These activities are presented as evidence of PluriCDMO’s ability to support complex cell-derived and cell-free processes.

Immunotherapy and intellectual property

Pluri emphasizes its work in immune cell engineering and cancer immunotherapy. The company has announced patents covering immune cell expansion technologies, including MAIT cells and TILs, within its 3D bioreactor system. It describes its placental allogeneic MAIT platform as offering potential advantages compared to conventional T cells, such as targeting tumors through multiple mechanisms, expressing chemokine receptors that facilitate migration to tumor sites, and exhibiting lower alloreactivity profiles.

By combining this cell biology with its large-scale expansion technology, Pluri believes it can enable commercial-scale production of immune cells that may be suitable for future off-the-shelf therapies. The company also notes that its platform has attracted interest in the growing TIL-focused research space, and that it aims to support both its own programs and potential collaborators in immunotherapy.

Collaborative network and business structure

Across its disclosures, Pluri describes a business structure built around a collaborative network of ventures and strategic partners. The company forms subsidiaries in specific verticals—such as cultivated meat, cacao, coffee and aesthetics—and enters into agreements with food companies, agtech leaders, public institutions and beauty brands. These relationships often include collaborator-funded proof-of-concept projects, licensing, joint ventures, royalty-bearing models or other commercial frameworks.

Pluri presents this approach as a way to apply its core 3D cell expansion platform across multiple industries that require scalable cell production, while sharing risk and aligning with partners that bring market access and domain expertise.

Corporate and capital markets context

Pluri Inc. is incorporated in Nevada and lists its common shares on Nasdaq and the Tel Aviv Stock Exchange under the symbol PLUR. The company has reported that it operates from Haifa, Israel. It has disclosed various capital markets activities, including private placements of common shares and warrants with entities beneficially owned by a significant shareholder and director, and equity-based compensation grants to executives and directors under its equity compensation plans.

Shareholder communications have highlighted revenue growth associated with the launch of new business verticals in CDMO and agtech, and the company has described its strategy as focusing on high-impact sectors such as cocoa and coffee, cultivated meat and regenerative medicine. Pluri also notes support from strategic investors who it says share its long-term vision for deploying its technology in global markets.

Position within biotechnology and manufacturing

Within the broader biotechnology and biological product manufacturing space, Pluri positions itself at the intersection of cell therapy, cell-based food and agriculture, and advanced manufacturing. Its emphasis on a single, versatile 3D cell expansion platform applied across multiple sectors is a central theme in its public materials. The company underscores themes of sustainability, climate resilience, food security and healthcare innovation, and presents its technology as a means to produce cells and cell-derived products at scale in controlled facilities, independent of traditional agricultural or environmental constraints.

FAQs about Pluri Inc. (PLUR)

• What does Pluri Inc. do?
  Pluri Inc. is a biotechnology company that develops cell-based products and technologies using a patented 3D cell expansion platform. It applies this platform in regenerative medicine, foodtech, agtech, aesthetics and CDMO services, and works through a network of subsidiaries and collaborations.
• How does Pluri’s 3D cell expansion platform work, according to the company?
  Pluri describes its platform as a state-of-the-art 3D cell expansion system that mimics a natural environment for cells within fully controlled, automated bioreactors. This setup is intended to enable accurate, scalable, cost-effective and consistent cell production from batch to batch.
• In which sectors does Pluri state that it operates?
  According to its public statements, Pluri operates in regenerative medicine, foodtech, agtech and aesthetics, and also offers Contract Development and Manufacturing Organization services to external clients.
• What are some of Pluri’s foodtech and agtech initiatives?
  Pluri has disclosed ventures such as Ever After Foods for cultivated meat, Kokomodo for cultivated cacao and Coffeesai for cell-based coffee. These subsidiaries use Pluri’s 3D cell expansion technology to develop cell-based alternatives to traditional meat, cacao and coffee production.
• What is PluriCDMO?
  PluriCDMO is Pluri’s CDMO division. The company states that it provides clients with access to its GMP facilities and patented bioreactor system for mass-scale cell expansion, supporting complex cell-derived and cell-free manufacturing processes, as illustrated by its collaboration with Remedy Cell.
• How is Pluri involved in immunotherapy research?
  Pluri reports that it has developed an immune cell platform focused on placental-derived MAIT cells and TILs, supported by patents for large-scale immune cell expansion. The company views this platform as a basis for potential future cancer immunotherapy applications and collaborations.
• What is Cellav and how does it relate to Pluri?
  Cellav Health and Aesthetics Ltd. is a wholly owned Pluri subsidiary focused on health and aesthetics. It uses Pluri’s 3D cell expansion platform to create exosome-based and other cell-derived ingredients and products for beauty and wellness, and has a commercial collaboration with Miss Universe Skincare.
• Where is Pluri based and on which exchanges does it trade?
  Pluri Inc. is a Nevada corporation that reports its principal operations in Haifa, Israel. Its common shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol PLUR.
• How does Pluri describe its business model?
  Pluri describes a model built around a core cell expansion platform and a collaborative network of ventures and partners. It forms subsidiaries in specific verticals and enters into strategic collaborations, often structured around proof-of-concept projects, licensing, joint ventures or royalty-bearing arrangements.
• What types of global challenges does Pluri aim to address?
  In its public materials, Pluri states that it seeks to address challenges such as sustainable food production, climate change impacts on agriculture, food scarcity, animal welfare concerns and unmet needs in healthcare and immunotherapy by applying its cell-based technologies.